Journal
IMMUNITY
Volume 54, Issue 8, Pages 1841-+Publisher
CELL PRESS
DOI: 10.1016/j.immuni.2021.06.015
Keywords
-
Categories
Funding
- Japan Agency for Medical Research and Development [JP19fk0108104, JP20fk0108104]
Ask authors/readers for more resources
Antibody titers against SARS-CoV-2 decrease over time, but the neutralizing potency against the original virus and variants actually improves with time. Late convalescent antibodies show increased neutralization potency against variants, suggesting that antibody response maturation enhances cross-neutralizing ability against circulating variants. This indicates that declining antibody titers may not necessarily mean declining protection.
Antibody titers against SARS-CoV-2 slowly wane over time. Here, we examined how time affects antibody potency. To assess the impact of antibody maturation on durable neutralizing activity against original SARS-CoV-2 and emerging variants of concern (VOCs), we analyzed receptor binding domain (RBD)-specific IgG antibodies in convalescent plasma taken 1-10 months after SARS-CoV-2 infection. Longitudinal evaluation of total RBD IgG and neutralizing antibody revealed declining total antibody titers but improved neutralization potency per antibody to original SARS-CoV-2, indicative of antibody response maturation. Neutralization assays with authentic viruses revealed that early antibodies capable of neutralizing original SARS-CoV-2 had limited reactivity toward B.1.351 (501Y.V2) and P.1 (501Y.V3) variants. Antibodies from late convalescents exhibited increased neutralization potency to VOCs, suggesting persistence of cross-neutralizing antibodies in plasma. Thus, maturation of the antibody response to SARS-CoV-2 potentiates cross-neutralizing ability to circulating variants, suggesting that declining antibody titers may not be indicative of declining protection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available